Literature DB >> 33929306

Progressive Pulmonary Infiltrates in a Man with Mediastinal Lymphoma.

Carla S Walti1, Guang-Shing Cheng2,3, Ajay K Gopal2,4, Joshua A Hill1,2,5.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33929306      PMCID： PMC8086548          DOI： 10.1513/AnnalsATS.202008-1012CC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  12 in total

1.  PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.

Authors:  Mizuki Nishino; Nikhil H Ramaiya; Hiroto Hatabu; F Stephen Hodi; Philippe F Armand
Journal:  Br J Haematol       Date:  2016-11-11       Impact factor: 6.998

2.  PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.

Authors:  Mizuki Nishino; Nikhil H Ramaiya; Mark M Awad; Lynette M Sholl; Jennifer A Maattala; Myriam Taibi; Hiroto Hatabu; Patrick A Ott; Philippe F Armand; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2016-08-17       Impact factor: 12.531

3.  Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Authors:  Jarushka Naidoo; Xuan Wang; Kaitlin M Woo; Tunc Iyriboz; Darragh Halpenny; Jane Cunningham; Jamie E Chaft; Neil H Segal; Margaret K Callahan; Alexander M Lesokhin; Jonathan Rosenberg; Martin H Voss; Charles M Rudin; Hira Rizvi; Xue Hou; Katherine Rodriguez; Melanie Albano; Ruth-Ann Gordon; Charles Leduc; Natasha Rekhtman; Bianca Harris; Alexander M Menzies; Alexander D Guminski; Matteo S Carlino; Benjamin Y Kong; Jedd D Wolchok; Michael A Postow; Georgina V Long; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

4.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 5.  Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.

Authors:  Jay A Fishman; John I Hogan; Marcela V Maus
Journal:  Clin Infect Dis       Date:  2019-08-30       Impact factor: 9.079

6.  Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Authors:  Myriam Delaunay; Jacques Cadranel; Amélie Lusque; Nicolas Meyer; Valérie Gounant; Denis Moro-Sibilot; Jean-Marie Michot; Judith Raimbourg; Nicolas Girard; Florian Guisier; David Planchard; Anne-Cécile Metivier; Pascale Tomasini; Eric Dansin; Maurice Pérol; Marion Campana; Oliver Gautschi; Martin Früh; Jean-David Fumet; Clarisse Audigier-Valette; Sébastien Couraud; Stéphane Dalle; Marie-Thérèse Leccia; Marion Jaffro; Samia Collot; Grégoire Prévot; Julie Milia; Julien Mazieres
Journal:  Eur Respir J       Date:  2017-08-10       Impact factor: 16.671

7.  Management of Immunotherapy-Related Toxicities, Version 1.2019.

Authors:  John A Thompson; Bryan J Schneider; Julie Brahmer; Stephanie Andrews; Philippe Armand; Shailender Bhatia; Lihua E Budde; Luciano Costa; Marianne Davies; David Dunnington; Marc S Ernstoff; Matthew Frigault; Brianna Hoffner; Christopher J Hoimes; Mario Lacouture; Frederick Locke; Matthew Lunning; Nisha A Mohindra; Jarushka Naidoo; Anthony J Olszanski; Olalekan Oluwole; Sandip P Patel; Sunil Reddy; Mabel Ryder; Bianca Santomasso; Scott Shofer; Jeffrey A Sosman; Momen Wahidi; Yinghong Wang; Alyse Johnson-Chilla; Jillian L Scavone
Journal:  J Natl Compr Canc Netw       Date:  2019-03-01       Impact factor: 11.908

8.  Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails.

Authors:  Hui Zhou; Xiaoyan Fu; Qian Li; Ting Niu
Journal:  Front Pharmacol       Date:  2019-05-01       Impact factor: 5.810

Review 9.  Pneumonitis and concomitant bacterial pneumonia in patients receiving pembrolizumab treatment: Three case reports and literature review.

Authors:  Jiho Jun; Sang-Ryung Lee; Ji Yean Lee; Min Joo Choi; Ji Yun Noh; Hee Jin Cheong; Woo Joo Kim; Joon Young Song
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

Review 10.  Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.

Authors:  Mizuki Nishino; Anita Giobbie-Hurder; Hiroto Hatabu; Nikhil H Ramaiya; F Stephen Hodi
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.